Kisspeptin
A reproductive-axis signaling peptide studied for its role in GnRH release and fertility-related endocrinology.
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Kisspeptin crosses your target, drops, or sets a new tracked low—without daily noise.
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research area, not by vendor shelf placement.
No major aliases are tracked for this profile yet.
No FDA label signal · 45 trials · 3301 PubMed results
Kisspeptin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Kisspeptin has 31 name-matched clinical trials (7 international) (highest phase: Phase 3) and 3302 PubMed-indexed publications and is not FDA-approved. 4 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What kisspeptin is
Kisspeptin is a signaling peptide involved in reproductive endocrine regulation, especially upstream effects on GnRH release.
Why it matters
It gives the library a more serious hormone-signaling category beyond growth hormone and weight loss. It is one of the clearer examples of a peptide that matters scientifically even when it is not a mainstream retail-market name.
Regulatory context
Kisspeptin is not an FDA-approved therapy for routine consumer use in the United States. It fits best in the investigational category.
Practical reading note
Hormone-linked peptides deserve extra care because endocrine language can make a product sound more established than it really is.